Type2 Diabetes Mellitus Clinical Trial
Official title:
The Effect of Multidomain Dietary Education in Type 2 Diabetic Adults
NCT number | NCT05892861 |
Other study ID # | 21-065-B |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 3, 2021 |
Est. completion date | March 31, 2023 |
Verified date | June 2023 |
Source | National Kaohsiung Normal University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this clinical trial is to [learn about cognitive stimulation by multidomain dietary education including the dietary board game via LINE in non-dementic type 2 diabetic adults. The main questions it aims to answer are: [Question 1: Could multi-domain dietary education as cognitive stimulation improve cognitive function?] [Question 2: Could multi-domain dietary education improve dietary control belief ?] [Question 3: Could multi-domain dietary education improve health behavior?] [Question 4]: Could multi-domain dietary education improve HbA1C, and lipid profile? Participants of experimental A group will receive a video about lifestyle education 5 minutes weekly for 3 weeks, a dietary board game 10 minutes weekly for 10 weeks, and a 24-hour dietary recall record 2 times weekly for 7 weeks. And participants of the experimental B group receive the usual clinical treatment. Then experimental A and Experimental B groups will cross over 12 weeks later. Researchers will compare the effect of intervention between the experimental A group and the experimental B group.
Status | Completed |
Enrollment | 40 |
Est. completion date | March 31, 2023 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: - The onset age of Diabetes Mellitus is more than 20 years old - Diagnosis of Diabetes according to past history including type 2 diabetes mellitus or drug history including oral anti-diabetic drugs Exclusion Criteria: - SLUMS meets the Dementia definition. - HbA1C = 10.0% - Rejected our study. - History of stroke. - History of depression. - History of psychiatric disease. - Visual impairment. - Hearing impairment. - Can't understand the informed consent |
Country | Name | City | State |
---|---|---|---|
Taiwan | Yong-Kang Clinic | Kaohsiung |
Lead Sponsor | Collaborator |
---|---|
National Kaohsiung Normal University | National Cheng-Kung University Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | The change of the awareness of complication and health behavior from baseline at 3 and 6 months | 8 questions about the complications of type 2 DM (stroke, blind, wood healing, amputation, CKD, CAD, hypoglycemia, and Dementia) by Linkert scale (the total score range is 8 to 40). Higher scores mean better change. | 12th week and 24th week | |
Other | The change of HbA1C from baseline at 3 and 6 months | biomedical data after phlebotomy (HbA1C in %), Higher scores mean worse change. | 12th week and 24th week | |
Other | The change of total cholesterol from baseline at 3 and 6 months | biomedical data after phlebotomy (total cholesterol in mg/dl). Higher scores mean worse change. | 12th week and 24th week | |
Other | The change of triglyceride from baseline at 3 and 6 months | biomedical data after phlebotomy (triglyceride in mg/dl). Higher scores mean worse change. | 12th week and 24th week | |
Other | The change of low-density lipoprotein cholesterol from baseline at 3 and 6 months | biomedical data after phlebotomy (low-density lipoprotein cholesterol in mg/dl). Higher scores mean worse change. | 12th week and 24th week | |
Other | The change of high-density lipoprotein cholesterol from baseline at 3 and 6 months | biomedical data after phlebotomy (high-density lipoprotein cholesterol in mg/dl). Higher scores mean worse change. | 12th week and 24th week | |
Other | The change of health behavior awareness from baseline at 3 and 6 months | 9 questions about health behavior (body weight measurement, foot care, blood pressure measurement, drug adherence, diet adherence, calculation of intake amount by hand when eating, smoking habits, drinking habits, and exercise habits) by Linkert scale (total score range is 9 to 45). Higher scores mean better change. | 12th week and 24th week | |
Other | The change of health behavior frequency per week from baseline at 3 and 6 months | 9 questions about health behavior (body weight measurement, foot care, blood pressure measurement, drug adherence, diet adherence, calculation of intake amount by hand when eating, smoking habits, drinking habits, and exercise habits) by Linkert scale (total score range is 9 to 45). Higher scores mean better change. | 12th week and 24th week | |
Primary | The change of cognitive function from baseline at 3 and 6 months | Saint Louis University Mental State examination, the total score range is 0~30. Higher scores mean better change. | 12th week & 24 week | |
Secondary | The change of dietary control belief from baseline at 3 and 6 months | 12 questions by Linkert scale (4 questions about dietary mastery items and 8 questions about dietary perceived constraints items) about dietary control belief(the total score range is 12 to 60) Higher scores mean better change. | 12th week and 24th week |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04082091 -
Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
|
||
Active, not recruiting |
NCT02248311 -
"Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population
|
N/A | |
Completed |
NCT02653300 -
A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)
|
Phase 2 | |
Completed |
NCT03655535 -
Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes
|
Phase 2 | |
Completed |
NCT03256747 -
Effects of Neuromuscular Electrical Stimulation on Glucose Variability in Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05343767 -
Investigate the Efficacy and Safety of Low-Glu in Patients Newly Diagnosed With Type II Diabetes Mellitus
|
N/A | |
Withdrawn |
NCT03675074 -
Neujia Anastomosis for Treatment of Obesity and Type II Diabetes
|
N/A | |
Withdrawn |
NCT03190798 -
Effects of Canagliflozin on Intravascular Volume and Hemodynamics
|
Phase 4 | |
Withdrawn |
NCT03437330 -
Empagliflozin Effect on Glucose Toxicity
|
Phase 4 | |
Withdrawn |
NCT03008395 -
Empowerment, Motivation and Medical Adherence (EMMA).
|
N/A | |
Not yet recruiting |
NCT05539066 -
AI Health Assistant and Type 2 Diabetes
|
N/A | |
Completed |
NCT03682445 -
Metabolic, Physical Responses To Exercise In Patients With Type 2 Diabetes Mellitus
|
N/A | |
Not yet recruiting |
NCT03239119 -
The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT03259789 -
Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
|
Phase 3 | |
Recruiting |
NCT03506230 -
Financial Incentives for Low Socioeconomic Diabetic Patients
|
N/A | |
Completed |
NCT03072407 -
MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM
|
Phase 1 | |
Completed |
NCT05668442 -
Feasibility of an Online Exercise Community Among Individuals With Type 2 Diabetes
|
||
Completed |
NCT02964572 -
Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes
|
N/A | |
Completed |
NCT02956044 -
Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin
|
Phase 1 | |
Completed |
NCT02628392 -
A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
|
N/A |